Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November

Rhea-AI Summary

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) announced participation in three investor conferences in November, focusing on their innovative oral enzyme therapeutics for metabolic and kidney disorders. The events include the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10 at 1:15 p.m. ET, the H.C. Wainwright & Co. 6th Annual Israel Conference on November 12 at 11:00 a.m. ET, and the Jefferies Virtual London Healthcare Conference from November 17-19, with one-on-one meetings available. Live audio webcasts can be accessed on their website.

NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:

29^th Annual Credit Suisse Virtual Healthcare Conference
Date: Tuesday, November 10
Presentation Time: 1:15 p.m. ET

H.C. Wainwright & Co. 6th Annual Israel Conference
Date: Thursday, November 12
Presentation Time: 11:00 a.m. ET

Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17- Thursday, November 19
Management will be available for one-on-one meetings.

Live audio webcasts of the Credit Suisse and H.C. Wainwright presentations will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

FAQ

What investor conferences will Allena Pharmaceuticals (ALNA) participate in November 2020?

Allena Pharmaceuticals will participate in the Credit Suisse Virtual Healthcare Conference on November 10, H.C. Wainwright & Co. 6th Annual Israel Conference on November 12, and the Jefferies Virtual London Healthcare Conference from November 17-19.

What is the date and time of Allena Pharmaceuticals' presentation at the Credit Suisse Conference?

Allena Pharmaceuticals will present at the Credit Suisse Virtual Healthcare Conference on November 10 at 1:15 p.m. ET.

How can investors access the presentations by Allena Pharmaceuticals (ALNA)?

Investors can access live audio webcasts of Allena Pharmaceuticals' presentations on their website under the 'Events and Presentations' section.

What is Allena Pharmaceuticals' lead product candidate?

Allena Pharmaceuticals' lead product candidate is reloxaliase, which is being evaluated for treating enteric hyperoxaluria.

What other product is Allena Pharmaceuticals developing and in what phase is it?

Allena Pharmaceuticals is also developing ALLN-346, currently in a Phase 1 clinical trial for treating hyperuricemia associated with gout and chronic kidney disease.